Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
Acute myeloid leukemia
Allogeneic stem cell transplantation
Cardiac toxicities
Targeted FLT3 inhibitor therapy
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
12
04
2023
accepted:
29
07
2023
medline:
11
9
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
ppublish
Résumé
The addition of midostaurin to standard chemotherapy has improved survival in patients with FLT3-mutated AML. However, the impact of midostaurin and other FLT3 inhibitors (FLT3i) on cardiovascular adverse events (CAEs) has not been studied in patients who underwent allogeneic hematopoietic stem cell transplantation in a real-world setting. We reviewed 132 patients with AML who were treated with intensive induction therapy and consecutive allogeneic stem cell transplantation at our institution (42 FLT3-mutated AML and 90 with FLT3 wildtype). We identified treatment with midostaurin and/or FLT3i as an independent risk factor for CAEs not resulting in higher non-relapse mortality (NRM) or impaired overall survival (OS). Hence, close monitoring for CAEs is warranted for these patients.
Identifiants
pubmed: 37552323
doi: 10.1007/s00277-023-05396-y
pii: 10.1007/s00277-023-05396-y
pmc: PMC10492676
doi:
Substances chimiques
midostaurin
ID912S5VON
Staurosporine
H88EPA0A3N
Protein Kinase Inhibitors
0
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
FLT3 protein, human
EC 2.7.10.1
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2903-2908Subventions
Organisme : Deutsche Krebshilfe
ID : Max-Eder Program
Informations de copyright
© 2023. The Author(s).
Références
Kindler T, Lipka DB, Fischer T (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116(24):5089–5102
doi: 10.1182/blood-2010-04-261867
pubmed: 20705759
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454–464
doi: 10.1056/NEJMoa1614359
pubmed: 28644114
pmcid: 5754190
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447
doi: 10.1182/blood-2016-08-733196
pubmed: 27895058
pmcid: 5291965
Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100(13):4372–4380
doi: 10.1182/blood-2002-05-1440
pubmed: 12393388
Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP et al (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 30(7):735–741
doi: 10.1200/JCO.2011.36.9868
pubmed: 22291086
Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110(4):1262–1270
doi: 10.1182/blood-2006-04-015826
pubmed: 17456725
Mead AJ, Gale RE, Hills RK, Gupta M, Young BD, Burnett AK et al (2008) Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 112(2):444–5 author reply 5
doi: 10.1182/blood-2008-02-140392
pubmed: 18606888
Dohner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA et al (2020) Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood 135(5):371–380
doi: 10.1182/blood.2019002697
pubmed: 31826241
pmcid: 6993016
Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA et al (2020) Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the acute leukemia working party of the european society for blood and marrow transplantation. Haematologica 105(6):1507–1516
doi: 10.3324/haematol.2019.243410
pubmed: 32241850
pmcid: 7271578
Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C et al (2020) Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol 38(26):2993–3002
doi: 10.1200/JCO.19.03345
pubmed: 32673171
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 381(18):1728–1740
doi: 10.1056/NEJMoa1902688
pubmed: 31665578
Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N et al (2019) Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 20(7):984–997
doi: 10.1016/S1470-2045(19)30150-0
pubmed: 31175001
Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H et al (2019) Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 133(8):840–851
doi: 10.1182/blood-2018-08-869453
pubmed: 30563875
Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL et al (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132(6):598–607
doi: 10.1182/blood-2018-01-821629
pubmed: 29875101
pmcid: 6085992
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919
doi: 10.1182/blood-2005-05-2004
pubmed: 15994282
pmcid: 1895304
Dulery R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E et al (2021) Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol 3(2):250–259
doi: 10.1016/j.jaccao.2021.02.011
pubmed: 34396331
pmcid: 8352028
Choudhary A, Manouchehri A, Moslehi J, Salem J (2020) Abstract 12978: identification of cardiovascular adverse effects associated with midostaurin - a WHO pharmacovigilance database analysis. Circulation 142:A12978